Connecticut Expands Psychedelics Pilot as FDA Decision Looms

Connecticut's legislature moved forward Tuesday with legislation to broaden a state pilot program exploring psychedelic-assisted therapy, positioning the state ahead of anticipated federal regulatory changes.

The Joint Committee on Public Health voted to favorably report a bill that would expand Connecticut's existing psychedelics research initiative, which currently focuses on military veterans. The measure comes as the FDA weighs approval decisions for MDMA and psilocybin therapies that could arrive within the next 12 to 18 months.

The expansion would add first responders and other populations to the pilot program's eligible participants, according to committee documents. Connecticut launched its initial psychedelic therapy pilot in 2023, making it one of roughly a dozen states exploring regulated access to these substances outside of federal approval pathways.

The Federal Timeline

The timing reflects a broader strategic shift among state lawmakers. The FDA is reviewing new drug applications for MDMA-assisted therapy for PTSD, with a decision expected by August 2024. Psilocybin therapy for treatment-resistant depression could follow in 2025, based on current clinical trial timelines.

"States are building the infrastructure now so they're not starting from scratch when FDA approval hits," said Mason Marks, a health law professor at Florida State University who tracks psychedelic policy. "Connecticut's approach—starting with veterans and expanding methodically—is becoming a model."

The Connecticut pilot currently operates through a partnership between state health officials and certified treatment centers. Participants receive psychedelic-assisted therapy in controlled clinical settings, with medical supervision and integration counseling. The program tracks outcomes data that state officials say will inform future policy decisions.

Industry Response

The bill's advancement drew support from advocacy organizations working on psychedelic access. Veterans groups have particularly backed Connecticut's approach, citing limited treatment options for PTSD and the lengthy wait times for existing therapies.

Connecticut joins Oregon, Colorado, and California in creating state-level frameworks for psychedelic therapy access. Oregon's licensed psilocybin service program launched in 2023 and has served several hundred clients. Colorado voters approved a similar measure in 2022, with implementation ongoing.

The measure still requires approval from the full legislature before reaching the governor's desk. Connecticut's legislative session runs through early June, giving lawmakers roughly two months to act on the bill.

What's Next

If enacted, the expanded pilot would likely begin enrolling new participant categories by late 2024 or early 2025. State health officials would need to develop protocols for screening and treating first responders, who face different trauma profiles than combat veterans.

The bill also includes provisions for data collection and reporting requirements, mandating that the pilot program submit annual reports to the legislature on participant outcomes, adverse events, and program costs. This data infrastructure could prove valuable if federal approval triggers broader state implementation.

Connecticut's Department of Mental Health and Addiction Services would oversee the expansion, working with existing treatment centers already participating in the veterans-focused pilot. The department has not yet released cost estimates for the broader program.

The psychedelics measure represents one piece of Connecticut's evolving approach to alternative therapies. The state legalized adult-use cannabis in 2021 and launched retail sales in 2023, creating regulatory frameworks that some officials suggest could inform psychedelic therapy oversight.

This article is based on original reporting by www.marijuanamoment.net.